PROPHY-VAP: Prevention of Early Ventilation Acquired Pneumonia (VAP) in Brain Injured Patients by a Single Dose of Ceftriaxone (PROPHY-VAP)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02265406 |
Recruitment Status :
Completed
First Posted : October 15, 2014
Last Update Posted : February 3, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Ventilation-associated pneumonia (VAP) is the main site of healthcare-associated infections in the brain injured patients, with an incidence rate of 22% to 58%. VAP increases morbi-mortality, length of stay in intensive care and overall management costs. The prevention of ICU nosocomial infections depends on several measures : orotracheal intubation route, maintaining tube cuff pressure between 25 and 30 cm of water (H2O), maintaining a semi-seated position >= 30°, nasal and oropharyngeal care at regular intervals, striving to avoid unscheduled extubation, and use of a written sedation-analgesia algorithm allowing for early weaning from ventilation. Two randomized study show that administration of antibiotic therapy after intubation reduces the risk of early VAP incidence. However, in clinical practice, its administration solely purposes of limiting VAP occurence is not presently recommended. Indeed, to date no placebo blind controlled study was been realized and the fear of development of bacterial resistance remains stronger than the efficiency of this prevention measure. This aim of the present study is to show by a placebo randomized study that 2g of Ceftriaxone within 8 hours post-intubation after a brain injury decrease the risk of occurence an early VAP.
Ancillary study An ancillary study is performed in 2 centres which routinely practice rectal swabs at admission and discharge of ICU, to survey intestinal flora (CHU of Angers and CHU of Rennes). The goal of this study is to compare the incidence of acquired cephalosporin resistant gram negative bacteria at the discharge of ICU between the 2 groups of patients, receiving or not ceftriaxone.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Early Ventilation Acquired Pneumonia in Brain Injured Patients | Drug: Anti-Infective Agents Drug: Placebo | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 354 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Prevention |
Official Title: | PROPHY-VAP: Prevention of Early Ventilation Acquired Pneumonia (VAP) in Brain Injured Patients by a Single Dose of Ceftriaxone |
Actual Study Start Date : | October 2015 |
Actual Primary Completion Date : | July 25, 2020 |
Actual Study Completion Date : | July 25, 2020 |
Arm | Intervention/treatment |
---|---|
Experimental: Ceftriaxone |
Drug: Anti-Infective Agents |
Placebo Comparator: Sodium Chloride |
Drug: Placebo |
- Incidence of early VAP, proportion of patients who develop a VAP within the 7 first day after mechanical ventilation (the 7th day included), confirm with microbiological culture, within all included patients. [ Time Frame: 30 months ]
- - Incidence of late VAP (> 7 jours) [ Time Frame: 30 months ]
- - Global incidence of VAP during intensive care period (limited to day 60) [ Time Frame: 30 months ]
- - Type of bacteria and their sensitivity for early or late VAP, [ Time Frame: 30 months ]
- - Time between inclusion and occurence of the first VAP (limited to day 28), [ Time Frame: 30 months ]
- - Length of the first period of mechanical ventilation during the intensive care period, [ Time Frame: 30 months ]
- - Time between inclusion and the first spontaneous ventilation test (limited to day 28), [ Time Frame: 30 months ]
- - Length of antibiotherapy during intensive care period, [ Time Frame: 30 months ]
- - Length of intensive care, limited to 60 days, [ Time Frame: 30 months ]
- - Length of stay in intensive care unit, limited to 60 days, [ Time Frame: 30 months ]
- - Length of stay at the hospital, limited to 60 days, [ Time Frame: 30 months ]
- - Neurological prognosis at the discharge of the intensive care unit, [ Time Frame: 30 months ]
- - Mortality at day 28 and 60. [ Time Frame: 30 months ]
- - Incidence of ventilated associated event (limited to day 60) [ Time Frame: 30 months ]
- - Comparison of the global incidence of VAP according to the diagnosis defined by "American Thoracic Society" or by "Centers for Disease Control" [ Time Frame: 30 months ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Brain injured patients with a Glasgow scale score ≤ 12 who require ventilation more than 48 hours
Exclusion Criteria:
- Patient with a high risk of death within the 48 first hours after admission,
- Patient intubated for more than12 hours
- Intubation after the 48th hours after admission
- Coverage to cardiopulmonary arrest
- Coma due to a tumor, an infectious disease or a cardiac arrest
- Previous hospitalisation within the last month before admission for coma
- béta-lactamines allergy
- Patient who receive already antibiotics at the admission for a previous infection
- Prophylactic antibiotic due to be done within 24 hours following the randomisation
- Patient Intubated through a tracheal tube with subglottic secretion aspiration
- Patient with a tracheotomy
- Patient or family refuse to be involved in the study
- Use of Ceftriaxone within 2 days before enrolment
- Participation in another research protocol focusing on an anti-infective treatment or on a measure decreasing the risk of infection
- Patients not affiliated to a social security scheme, Pregnant woman or breast-feeding mother, Patients deprived of their liberty by judicial or administrative decision
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02265406
France | |
University Hospital of Angers | |
Angers, France, 49933 | |
CHU | |
Bordeaux, France | |
CHRU | |
Montpellier, France | |
University Hospital of Nantes | |
Nantes, France, 44093 | |
University Hospital of Poitiers | |
Poitiers, France, 86021 | |
University Hospital of Rennes | |
Rennes, France, 35033 | |
Thomas GEERAERTS | |
Toulouse, France, 31059 | |
Djilali ELAROUSSI | |
Tours, France, 37000 |
Responsible Party: | Poitiers University Hospital |
ClinicalTrials.gov Identifier: | NCT02265406 |
Other Study ID Numbers: |
PROPHY-VAP |
First Posted: | October 15, 2014 Key Record Dates |
Last Update Posted: | February 3, 2021 |
Last Verified: | February 2021 |
Pneumonia Respiratory Tract Infections Infections |
Lung Diseases Respiratory Tract Diseases Anti-Infective Agents |